^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    INCB62079

    i
    Other names: INCB62079, INCB 62079, INCB062079, INCB-062079, INCB-62079
    Associations

    News

    Trials
    Company:
    Incyte
    Drug class:
    FGFR4 inhibitor
    Related drugs:
    Associations

    News

    Trials
    over1year
    First-in-Human Study of INCB062079, a Fibroblast Growth Factor Receptor 4 Inhibitor, in Patients with Advanced Solid Tumors. (PubMed, Target Oncol)
    With C4 cut-off and prophylactic bile acid sequestrant implementation, INCB062079 demonstrated a manageable safety profile and evidence of target inhibition. In view of the rarity of FGF19/FGFR4 alterations and slow patient accrual, the study was terminated before establishing an MTD.
    P1 data • Clinical Trial,Phase I • Journal • Metastases
    |
    FGF19 (Fibroblast growth factor 19) • FGFR4 (Fibroblast growth factor receptor 4)
    |
    INCB62079